BioMarin Pharmaceutical Inc. (BMRN)

NASDAQ: BMRN · USD

$56.0

+0.65 (+1.2%)· Recorded snapshot

Market cap	10.8B
Revenue (ttm)	3.4B
Net income (ttm)	73M
EPS (ttm)	$0.38
Shares out	193.6M
P/E (trailing)	147.8x
P/E (forward)	12.2x
Volume	1,493,177
Beta	0.22

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 3.4B
Net income (ttm): 73M
EPS (ttm): $0.38
P/E (trailing): 147.8x
P/E (forward): 12.2x
Market cap: 10.8B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Halten

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E12.2

P25 n/aP50 n/aP75 n/a

Trailing P/E147.8

P25 n/aP50 n/aP75 n/a

ROE1.2

P25 n/aP50 n/aP75 n/a

ROIC3.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All BMRN indicators

Market & fundamental data

Available fields

271

Groups with data

Currency

USD

Showing 271 of 271 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001048477
Company name	BioMarin Pharmaceutical Inc.
Country	United States
Country code	US
CUSIP number	09061G101
Earnings date	2026-11-02
Earnings time	amc
Employees	3,221
Employees change	181
Employees growth	5.95%
Enterprise value	$14.2B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1996
Industry	Biotechnology
IPO date	1999-07-23
Is primary listing	Yes
Is SPAC	No
ISIN number	US09061G1013
Last 10-K release date	2026-02-26
Last earnings date	2026-08-06
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$10.8B
Market cap category	Large-Cap
Next earnings date	2026-11-02
Options	Yes
Price	$56.00
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	BMRN
U.S. state	California
Website	https://www.biomarin.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	22.05x
Average P/E ratio (10Y)	135.19x
Average P/E ratio (3Y)	60.01x
Average P/E ratio (5Y)	157.57x
Earnings yield	0.68%
EV/Earnings	193.42x
EV/EBIT	28.24x
EV/EBITDA	21.87x
EV/FCF	19.12x
EV/Sales	4.14x
FCF / EV yield	5.23%
FCF yield	6.84%
Forward EV/Sales	3.28x
Forward P/E	12.18x
Forward P/S	2.5x
Graham number	16.68927
Graham upside	-70.05%
Lynch fair value	$1.89
Lynch upside	-96.6%
P/(FCF - SBC) ratio	20.63x
P/(OCF - SBC) ratio	16.81x
P/B ratio	1.69x
P/E ratio	147.77x
P/FCF ratio	14.61x
P/OCF ratio	12.58x
P/S ratio	3.17x
PEG ratio	0.42x
Price / tangible book value	13.71x
Price/EBITDA ratio	16.71x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	14.67%
EBITDA margin	18.94%
Effective tax rate	51.06%
FCF margin	21.67%
Gross margin	50.97%
Operating margin	14.67%
Pretax margin	4.38%
Profit margin	2.14%
Profit per employee	$22,655
Profitable quarters	2
Profitable years	4
Revenue per employee	$1.1M
ROA	3.26%
ROA (5Y)	2.28%
ROCE	4.97%
ROE	1.18%
ROE (5Y)	3.83%
ROIC	3.24%
ROIC (5Y)	3.88%
SBC / revenue	6.32%
Tax / revenue	2.24%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	-88.85%
EPS growth (Q)	-81.3%
EPS growth (QoQ)	-57.65%
EPS growth 3Y	-10.29%
EPS growth 5Y	-38.77%
EPS growth years	0
FCF growth	6.23%
FCF growth (Q)	-17.17%
FCF growth (QoQ)	-30.26%
FCF growth 3Y	144.98%
FCF growth 5Y	33.6%
Gross profit growth	-1.29%
Gross profit growth (Q)	15.11%
Gross profit growth 3Y	18.44%
Gross profit growth 5Y	18.57%
Net income growth	-88.9%
Net income growth (Q)	-81.39%
Net income growth (QoQ)	-57.58%
Net income growth 3Y	-9.97%
Net income growth 5Y	-38.61%
Net income growth years	0
OCF growth	11.78%
OCF growth (Q)	-9.26%
OCF growth (QoQ)	-23.81%
OCF growth 3Y	74.52%
OCF growth 5Y	26.07%
Operating income growth	-35.61%
Operating income growth (Q)	-24.36%
Operating income growth 3Y	58.48%
Revenue growth	11.2%
Revenue growth (Q)	19.91%
Revenue growth (QoQ)	29.17%
Revenue growth 10Y	13.34%
Revenue growth 3Y	15.09%
Revenue growth 5Y	12.19%
Revenue growth quarters	18
Revenue growth years	4

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-118.9M
Depreciation and amortization	$145.6M
EBIT	$499.7M
EBITDA	$645.3M
EPS	$0.38
FCF per share	$3.81
Financing cash flow	$3.6B
Free cash flow	$738.2M
Free cash flow minus SBC	$522.9M
Gross profit	$1.7B
Income taxes	$76.1M
Investing cash flow	$-4.7B
Net borrowing	$3.7B
Net cash flow	$-339.8M
Net income	$73M
Operating cash flow minus SBC	$641.8M
Operating income	$499.7M
Revenue	$3.4B
Stock-based compensation	$215.3M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	1.9
Book value per share	$32.66
Debt / EBITDA	6.41
Debt / equity	0.66
Debt / FCF	5.69
Goodwill	$655.7M
Interest coverage	5.98
Long-term assets	$7.8B
Long-term liabilities	$3.7B
Net cash (debt)	$-3.3B
Net cash / market cap	-30.86%
Net debt / EBITDA	5.16
Net debt / equity	0.53
Net debt / FCF	4.51
Piotroski F-Score	4
Property, plant and equipment	$990M
Shareholders' equity	$6.3B
Tangible book value	$786.6M
Tangible book value per share	$4.06
Total assets	$11.7B
Total cash	$874M
Total debt	$4.2B
Total liabilities	$5.4B
WACC	4.19%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.36
Current assets	$4B
Current liabilities	$1.7B
Current ratio	2.39
Inventory turnover	1.07
Net working capital	$2.1B
Quick ratio	1.16
Working capital	$2.3B
Working capital turnover	1.26

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-0.61%
Dividend yield	0%
Shareholder yield	-0.61%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-30.88%
10Y return CAGR	-3.63%
10Y total return	-30.88%
150-day SMA	$58.42
15Y price change	68.37%
15Y return CAGR	3.53%
15Y total return	68.37%
1D price change	1.17%
1M price change	-7.07%
1M total return	-7.07%
1W price change	1.43%
1W total return	1.43%
1Y price change	6.32%
1Y return CAGR	6.33%
1Y total return	6.32%
20-day SMA	$55.80
200-day SMA	$58.41
20Y price change	246.96%
20Y return CAGR	6.42%
20Y total return	246.96%
3M price change	-7.08%
3M total return	-7.08%
3Y price change	-30.58%
3Y return CAGR	-11.45%
3Y total return	-30.58%
50-day SMA	$61.04
50-day SMA vs 200-day SMA	50over200
52-week high	$70.98
52-week high date	2026-08-12
52-week low	$49.26
52-week low date	2026-05-18
5Y price change	-21.92%
5Y return CAGR	-4.83%
5Y total return	-21.92%
6M price change	4.08%
6M total return	4.08%
All-time high	$151.75
All-time high date	2015-07-20
All-time low	$3.57
All-time low date	2002-09-04
Average true range (ATR)	$1.59
Average volume	2.5M
Beta (1Y)	0.39
Beta (2Y)	0.5
Beta (5Y)	0.22
Change from 52-week high	-21.1%
Change from 52-week low	13.69%
Change from all-time high	-63.1%
Change from all-time low	1,468.63%
Change from open	1.99%
Day's gap	-0.79%
Dollar volume	$83.6M
High price	$56.14
Low price	$54.85
Monthly RSI	42.73
Open price	$54.91
Position in 52-week range	89.15%
Premarket change	-0.6%
Premarket close	$55.35
Premarket price	$55.02
Premarket volume	8.1K
Previous close	$55.35
Price vs 150-day SMA	-4.15%
Price vs 20-day SMA	0.37%
Price vs 200-day SMA	-4.13%
Price vs 50-day SMA	-8.25%
Relative volume	0.61
RSI	43.27
Sharpe ratio	0.23
Sharpe ratio (3Y)	-0.35
Sharpe ratio (5Y)	-0.14
Sortino ratio	0.62
Sortino ratio (3Y)	-0.32
Sortino ratio (5Y)	-0.02
Volume	1.5M
Weekly RSI	42.73
YTD price change	-5.77%
YTD total return	-5.77%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	192.6M
Float percentage	99.51%
Shares change (QoQ)	-1.62%
Shares change (YoY)	0.61%
Shares held by insiders	0.4%
Shares held by institutions	102.58%
Shares outstanding	193.6M
Short % of float	5.98%
Short % of shares	5.95%
Short ratio	5.7 days

Deeper analysis on BMRN

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this BMRN report

Is a complete BMRN research report available?

No complete published report is available for BioMarin Pharmaceutical Inc. (BMRN) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

BioMarin Pharmaceutical Inc. (BMRN)

Price

Financial snapshot

Fair-value bridge

Latest news · BMRN

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All BMRN indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on BMRN

Frequently asked questions